Literature DB >> 2784064

Biphenotypic leukemic lymphocyte precursors in CD2+CD19+ acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues.

F M Uckun1, A Muraguchi, J A Ledbetter, T Kishimoto, R T O'Brien, J S Roloff, K Gajl-Peczalska, A Provisor, B Koller.   

Abstract

During detailed immunophenotypic analyses of marrow blasts from 336 acute lymphoblastic leukemia (ALL) patients, a very small percentage of cases reactive with B-cell-directed as well as T-cell-directed monoclonal antibodies (MoAbs) were identified. Five ALL cases were biphenotypic since they coexpressed CD2 (Tp50) and CD19 (Bp95) antigens at the single-cell level. The composite immunophenotype of these biphenotypic ALL cases was [TdT+HLA-ABC+CD2+CD3-CD10+CD13-CD14-CD16-CD19+CD20+ ++-CD21-CD33-CD34+Bgp95-C mu- slg-]. Low-molecular-weight B-cell growth factor (LMW-BCGF), recombinant interleukin-2 (rIL-2), and rIL-3 stimulated the proliferative activity of biphenotypic leukemic lymphocyte precursors without inducing differentiation. In the presence of the phorbol ester TPA, leukemic blasts from two cases differentiated along the B precursor pathway to the [CD2-CD10+CD19+CD20+C mu+slg-] pre-B cell stage. Biphenotypic ALL cases did not share a common configuration and gene rearrangement pattern of the immunoglobulin heavy chain genes or T-cell receptor (TCR) genes. Three cases had rearranged C mu genes but germline TCR genes, one case showed rearrangement of both C mu and TCR genes, and the remaining case had rearranged TCR genes but germline C mu genes. All five patients attained prompt remission after standard induction chemotherapy. Three to four years after initial diagnosis, four patients are now off chemotherapy and remain alive in their first remission. One patient relapsed at 3 years, 7 months, but promptly achieved complete remission after reinduction chemotherapy and remains in second remission off chemotherapy greater than 3 years after her reinduction therapy. With two-color immunofluorescence staining techniques and multiparameter flow cytometric analyses, we identified a small population of CD2+CD19+ lymphoid cells in fetal livers (FLs) and fetal bone marrows (FBMs), which may represent the putative normal counterparts of biphenotypic ALL blasts. A CD2+CD19+ normal biphenotypic lymphoid precursor cell line, designated FL 8.2 CD2+, was established from an FL of 8-weeks of gestational age by Epstein-Barr virus (EBV)-induced blastoid transformation. The composite immunophenotype of FL 8.2 CD2+ cell line was [TdT+HLA-ABC+HLA-DR+ CD2+CD5-CD7-CD10+/-CD13-CD19+CD20-CD21+ CD22+CD33-CD34+/-Bgp95-CDw40+C mu-slgD-slgM-]. FL 8.2 CD2+ cells showed germline patterns of immunoglobulin heavy-chain joining region, heavy-chain constant region, kappa light-chain constant region genes, and TCR beta-chain genes. Cross-linking of CD2 as well as CD19 antigens on FL 8.2 CD2+ cells caused an increase of intracellular ionized calcium.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784064

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  Early embryonal/fetal lymphopoietic ontogeny and leukemogenesis.

Authors:  G Prindull
Journal:  Ann Hematol       Date:  1991-12       Impact factor: 3.673

2.  Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia.

Authors:  L Sun; N Heerema; L Crotty; X Wu; C Navara; A Vassilev; M Sensel; G H Reaman; F M Uckun
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

3.  Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Yousif Matloub; Bruce C Bostrom; Stephen P Hunger; Linda C Stork; Anne Angiolillo; Harland Sather; Mei La; Julie M Gastier-Foster; Nyla A Heerema; Scott Sailer; Patrick J Buckley; Blythe Thomson; Catherine Cole; James B Nachman; Gregory Reaman; Naomi Winick; William L Carroll; Meenakshi Devidas; Paul S Gaynon
Journal:  Blood       Date:  2011-05-11       Impact factor: 22.113

4.  Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia.

Authors:  Fatih M Uckun; Dorothea E Myers; Sanjive Qazi; Zahide Ozer; Rebecca Rose; Osmond J D'Cruz; Hong Ma
Journal:  J Clin Invest       Date:  2015-01-26       Impact factor: 14.808

5.  Interleukin 7 receptor engagement stimulates tyrosine phosphorylation, inositol phospholipid turnover, proliferation, and selective differentiation to the CD4 lineage by human fetal thymocytes.

Authors:  F M Uckun; L Tuel-Ahlgren; V Obuz; R Smith; I Dibirdik; M Hanson; M C Langlie; J A Ledbetter
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

6.  Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group.

Authors:  Yousif Matloub; Karen R Rabin; Lingyun Ji; Meenakshi Devidas; Johann Hitzler; Xinxin Xu; Bruce C Bostrom; Linda C Stork; Naomi Winick; Julie M Gastier-Foster; Nyla A Heerema; Eileen Stonerock; William L Carroll; Stephen P Hunger; Paul S Gaynon
Journal:  Blood Adv       Date:  2019-06-11

7.  Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.

Authors:  Yousif Matloub; Susan Lindemulder; Paul S Gaynon; Harland Sather; Mei La; Emmett Broxson; Rochelle Yanofsky; Raymond Hutchinson; Nyla A Heerema; James Nachman; Marilyn Blake; Linda M Wells; April D Sorrell; Margaret Masterson; John F Kelleher; Linda C Stork
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

8.  Intrinsic radiation resistance of primary clonogenic blasts from children with newly diagnosed B-cell precursor acute lymphoblastic leukemia.

Authors:  F M Uckun; W Jaszcz; M Chandan-Langlie; K G Waddick; K Gajl-Peczalska; C W Song
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

9.  E2A expression, nuclear localization, and in vivo formation of DNA- and non-DNA-binding species during B-cell development.

Authors:  Y Jacobs; C Vierra; C Nelson
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

10.  Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.

Authors:  Elisabeth Paietta; Kathryn G Roberts; Victoria Wang; Zhaohui Gu; Georgina A N Buck; Deqing Pei; Cheng Cheng; Ross L Levine; Omar Abdel-Wahab; Zhongshan Cheng; Gang Wu; Chunxu Qu; Lei Shi; Stanley Pounds; Cheryl L Willman; Richard Harvey; Janis Racevskis; Jan Barinka; Yanming Zhang; Gordon W Dewald; Rhett P Ketterling; David Alejos; Hillard M Lazarus; Selina M Luger; Letizia Foroni; Bela Patel; Adele K Fielding; Ari Melnick; David I Marks; Anthony V Moorman; Peter H Wiernik; Jacob M Rowe; Martin S Tallman; Anthony H Goldstone; Charles G Mullighan; Mark R Litzow
Journal:  Blood       Date:  2021-09-16       Impact factor: 25.476

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.